#### BIOMARIN PHARMACEUTICAL INC

Form 4

Common

Common

Stock

Stock

11/03/2008(2)

11/03/2008

November 05, 2008

November (	05, 2008								
FORM	OMB APPROVAL								
	UNITED		RITIES AND EXCashington, D.C. 20:		OMMISSION	OMB Number:	3235-0287 January 31,		
Check the if no lon subject the contract of th	iger STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							
Section Form 4 of Form 5 obligation may con See Instruction 1(b).	or Filed pur Section 17(	SECURITIES  Estimated average burden hours per response  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type	Responses)								
1. Name and A	Address of Reporting EMIL D	Symbol BIOM	er Name <b>and</b> Ticker or [ARIN PHARMAC]		5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)				
(Last)  C/O BIOM PHARMAO DIGITAL I	ARIN CEUTICAL INC.	(Month 10/31/	of Earliest Transaction /Day/Year) /2008		Director 10% Owner _X Officer (give title Other (specify below) Chief Medical Officer				
	(Street)		nendment, Date Original (onth/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NOVATO,	CA 94949				Form filed by Mo Person	ore than One Re	porting		
(City)	(State)	(Zip) Ta	ble I - Non-Derivative S	Securities Acqu	iired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Transactionor Dispose Code (Instr. 3, 4	ed of (D)	5. Amount of Securities Beneficially Owned Following	Ownership Indirect Form: Benefi Direct (D) Owner or Indirect (Instr.	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V Amount	(A) or (D) Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)			
Common Stock	10/31/2008(1)		P V 317	A \$ 13.354	115,621	D			
Common Stock	11/03/2008(2)	11/03/2008	M 16,000	A \$ 6.13	131,621	D			
~				\$					

17,000 D

M

18.114 114,621

4,654

(3)

D

I

Shares

held by

#### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

spouse.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	th/Day/Year) Execution Date, if TransactiorDerivative any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 6.13	11/03/2008(2)	11/03/2008	M	16,000	01/07/2005(4)	01/06/2015	Common Stock	16,000

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949

Chief Medical Officer

### **Signatures**

G. Eric Davis, Attorney-in-Fact

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to the Employee Stock Purchase Plan.
- (2) Transaction made pursuant to a Rule 10b5-1 Trading Plan executed March 1, 2008.

(3)

Reporting Owners 2

#### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

The price in Column 4 is a weighted average price. The prices actually received ranged from \$18.56 to \$19.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(4) Original option grant vested 1/48th on 1/7/2005 and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.